Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Riedel R, Fassunke J, Tumbrink HL, Scheel AH, Heydt C, Hieggelke L, Scheffler M, Heimsoeth A, Nogova L, Michels S, Weber JP, Fischer RN, Eisert A, Westphal T, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Castiglione R, Pappesch R, Rehker J, Jürgens J, Stoelben E, Bunck A, Kobe C, Merkelbach-Bruse S, Sos ML, Büttner R, Wolf J. Riedel R, et al. Among authors: scheel ah. Eur J Cancer. 2023 Jan;179:124-135. doi: 10.1016/j.ejca.2022.11.010. Epub 2022 Nov 15. Eur J Cancer. 2023. PMID: 36521334
PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM, Scheel AH, Ozretić L, George J, Thomas RK, Hagemann T, Zander T, Wolf J, Buettner R. Schultheis AM, et al. Among authors: scheel ah. Eur J Cancer. 2015 Feb;51(3):421-6. doi: 10.1016/j.ejca.2014.12.006. Epub 2015 Jan 9. Eur J Cancer. 2015. PMID: 25582496 Free article.
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J. Michels S, et al. Among authors: scheel ah. J Thorac Oncol. 2016 Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016. J Thorac Oncol. 2016. PMID: 26762747 Free article.
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Ortiz-Cuaran S, et al. Among authors: scheel ah. Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252416
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R. Scheel AH, et al. Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8. Mod Pathol. 2016. PMID: 27389313 Free article.
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Scheel AH, Ansén S, Schultheis AM, Scheffler M, Fischer RN, Michels S, Hellmich M, George J, Zander T, Brockmann M, Stoelben E, Groen H, Timens W, Perner S, von Bergwelt-Baildon M, Büttner R, Wolf J. Scheel AH, et al. Oncoimmunology. 2016 Mar 16;5(5):e1131379. doi: 10.1080/2162402X.2015.1131379. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467949 Free PMC article.
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.
George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Jang SJ, Petersen I, Büttner R, Harris CC, Yokota J, Thomas RK, Kohno T. George J, et al. Among authors: scheel ah. Clin Cancer Res. 2017 Mar 1;23(5):1220-1226. doi: 10.1158/1078-0432.CCR-16-1069. Epub 2016 Sep 12. Clin Cancer Res. 2017. PMID: 27620277 Free PMC article.
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML. Plenker D, et al. Among authors: scheel ah. Sci Transl Med. 2017 Jun 14;9(394):eaah6144. doi: 10.1126/scitranslmed.aah6144. Sci Transl Med. 2017. PMID: 28615362 Free PMC article.
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM. Plenker D, et al. Among authors: scheel ah. Clin Cancer Res. 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28. Clin Cancer Res. 2018. PMID: 29284707
55 results